Market Overview:
The global mantle cell lymphoma therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of mantle cell lymphoma, rising awareness about available treatment options, and the launch of novel therapies. The global mantle cell lymphoma therapeutics market is segmented on the basis of type into combination therapy and monotherapy. On the basis of application, it is segmented into hospital, research institute, and other segments. Geographically, it is segmented into North America, Latin America, Europe Asia Pacific and Middle East & Africa.
Product Definition:
Mantle Cell Lymphoma Therapeutics is a type of cancer that affects the mantle cell lymphoma, which is a type of white blood cell. This cancer can develop in any part of the body, but it most commonly affects the lymph nodes in the neck, chest, and armpits. Mantle Cell Lymphoma Therapeutics is important because it can help to treat this form of cancer.
Combination Therapy:
Combo therapy is a treatment approach in which more than one drug or medication is used together to treat an illness. In cancer treatment, combination therapies are used with chemotherapy and radiation therapy to enhance the effectiveness of these treatments. Some of the medications that are commonly used in combination with other drugs include immuno-oncology agents, mTOR inhibitors, Vascular Endothelial Growth Factor (VEGF) inhibitors and Bcl-2 family members.
Monotherapy:
Monotherapy is a treatment method that requires only one drug or medication for the treatment of an illness. Monotherapy can be used in various types of lymphomas such as diffuse large B-cell lymphoma, mantle cell lymphoma, and others. The most common type of monotherapy used in MCL (Mantle Cell Lymphoma) therapeutics is Rituximab (Rituxan).
Application Insights:
The other application segment held the largest share of more than 60.0% in 2017. Other applications include extramedical sites and metastasis to other organs/tumors such as brain, lungs, liver and bones. The hospital application segment is expected to witness the fastest growth during the forecast period owing to increasing cases of cancer across the globe which has resulted in increased demand for mantle cell lymphoma therapies worldwide.
MCL is a type of white blood cells tumor which predominantly affects elderly people above 60 years age group due to its rare incidence till date and hence there is an unmet need for effective treatment options with high cure rates globally that can be provided at affordable prices thereby fueling industry growth over the forecast period (2017-2030).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased research activities by companies, and high healthcare expenditure in this region. Moreover, favorable government initiatives pertaining to mantle cell lymphoma are also expected to drive regional growth over the forecast period. For instance, as part of its efforts toward creating awareness about MCL and its treatment options in North America; Novartis is funding various programs such as “Fighting for a Cure†which aims at increasing access to care for patients with MCL & NHL throughout North America. Asia Pacific is estimated to be fastest-growing region during the forecast period owing to unmet needs regarding diagnosis & treatment of MCL & NHL coupled with rapidly improving healthcare infrastructure and growing patient awareness levels about available treatments for mantle cell lymphoma across this region.
Growth Factors:
- Increasing incidence of mantle cell lymphoma (MCL)
- Growing demand for better and more efficacious therapies for MCL patients
- Rising awareness about MCL and its treatment options among physicians and patients alike
- Availability of novel, targeted therapies that are specifically approved for the treatment of MCL
- Continued investment in research and development aimed at improving our understanding of MCL biology and developing new treatments
Scope Of The Report
Report Attributes
Report Details
Report Title
Mantle Cell Lymphoma Therapeutics Market Research Report
By Type
Combination Therapy, Monotherapy
By Application
Hospital, Research Institute, Other
By Companies
Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
204
Number of Tables & Figures
143
Customization Available
Yes, the report can be customized as per your need.
Global Mantle Cell Lymphoma Therapeutics Market Report Segments:
The global Mantle Cell Lymphoma Therapeutics market is segmented on the basis of:
Types
Combination Therapy, Monotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Research Institute, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan Plc
- AstraZeneca Plc
- Celgene Corp.
- Johnson & Johnson Services Inc.
- Takeda Pharmaceutical Co. Ltd.
Highlights of The Mantle Cell Lymphoma Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Combination Therapy
- Monotherapy
- By Application:
- Hospital
- Research Institute
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Mantle Cell Lymphoma Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Mantle Cell Lymphoma Therapeutics is a biotechnology company focused on the development of novel therapies for patients with mantle cell lymphoma (MCL). The company's lead product candidate, MK-3475, is an investigational therapy that has shown potential to improve patient outcomes in Phase 2 clinical trials.
Some of the key players operating in the mantle cell lymphoma therapeutics market are Allergan Plc, AstraZeneca Plc, Celgene Corp., Johnson & Johnson Services Inc., Takeda Pharmaceutical Co. Ltd..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Mantle Cell Lymphoma Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Mantle Cell Lymphoma Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Mantle Cell Lymphoma Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Mantle Cell Lymphoma Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Mantle Cell Lymphoma Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Mantle Cell Lymphoma Therapeutics Market Size and Y-o-Y Growth
4.5.2 Mantle Cell Lymphoma Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Mantle Cell Lymphoma Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Mantle Cell Lymphoma Therapeutics Market Size Forecast by Type
5.2.1 Combination Therapy
5.2.2 Monotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Mantle Cell Lymphoma Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Mantle Cell Lymphoma Therapeutics Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Research Institute
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Mantle Cell Lymphoma Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Mantle Cell Lymphoma Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Mantle Cell Lymphoma Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Mantle Cell Lymphoma Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Mantle Cell Lymphoma Therapeutics Market Size Forecast by Type
9.6.1 Combination Therapy
9.6.2 Monotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Mantle Cell Lymphoma Therapeutics Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Research Institute
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Mantle Cell Lymphoma Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Mantle Cell Lymphoma Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Mantle Cell Lymphoma Therapeutics Market Size Forecast by Type
10.6.1 Combination Therapy
10.6.2 Monotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Mantle Cell Lymphoma Therapeutics Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Research Institute
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Mantle Cell Lymphoma Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Mantle Cell Lymphoma Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Mantle Cell Lymphoma Therapeutics Market Size Forecast by Type
11.6.1 Combination Therapy
11.6.2 Monotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Mantle Cell Lymphoma Therapeutics Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Research Institute
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Mantle Cell Lymphoma Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Mantle Cell Lymphoma Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Mantle Cell Lymphoma Therapeutics Market Size Forecast by Type
12.6.1 Combination Therapy
12.6.2 Monotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Mantle Cell Lymphoma Therapeutics Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Research Institute
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Mantle Cell Lymphoma Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Mantle Cell Lymphoma Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Mantle Cell Lymphoma Therapeutics Market Size Forecast by Type
13.6.1 Combination Therapy
13.6.2 Monotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Mantle Cell Lymphoma Therapeutics Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Research Institute
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Mantle Cell Lymphoma Therapeutics Market: Competitive Dashboard
14.2 Global Mantle Cell Lymphoma Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Allergan Plc
14.3.2 AstraZeneca Plc
14.3.3 Celgene Corp.
14.3.4 Johnson & Johnson Services Inc.
14.3.5 Takeda Pharmaceutical Co. Ltd.
